Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 234

1.

Evaluation of a Medicaid Lock-in Program: Increased Use of Opioid Use Disorder Treatment but No Impact on Opioid Overdose Risk.

Naumann RB, Roberts AW, Marshall SW, Skinner AC.

Med Care. 2019 Jan 8. doi: 10.1097/MLR.0000000000001058. [Epub ahead of print]

PMID:
30629016
2.

BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines.

Merino D, Kelly GL, Lessene G, Wei AH, Roberts AW, Strasser A.

Cancer Cell. 2018 Dec 10;34(6):879-891. doi: 10.1016/j.ccell.2018.11.004. Review.

PMID:
30537511
3.

A phase 1b dose-escalation and expansion study of the BCL-2 inhibitor venetoclax combined with tamoxifen in ER and BCL-2-positive metastatic breast cancer.

Lindeman GJ, Lok SW, Whittle JR, Vaillant F, Teh CE, Lo LL, Policheni AN, Bergin ART, Desai J, Ftouni S, Gandolfo LC, Liew D, Liu HK, Mann GB, Moodie K, Murugasu A, Pal B, Roberts AW, Rosenthal MA, Shackleton K, Silva MJ, Siow ZR, Smyth GK, Taylor L, Travers A, Yeo B, Yeung MM, Zivanovic Bujak A, Dawson SJ, Gray DHD, Visvader JE.

Cancer Discov. 2018 Dec 5. pii: CD-18-1151. doi: 10.1158/2159-8290.CD-18-1151. [Epub ahead of print]

PMID:
30518523
4.

Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia.

Blombery P, Anderson MA, Gong JN, Thijssen R, Birkinshaw RW, Thompson ER, Teh CE, Nguyen T, Xu Z, Flensburg C, Lew TE, Majewski IJ, Gray DHD, Westerman DA, Tam CS, Seymour JF, Czabotar PE, Huang DCS, Roberts AW.

Cancer Discov. 2018 Dec 4. pii: CD-18-1119. doi: 10.1158/2159-8290.CD-18-1119. [Epub ahead of print]

PMID:
30514704
5.

Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma.

Agarwal R, Chan YC, Tam CS, Hunter T, Vassiliadis D, Teh CE, Thijssen R, Yeh P, Wong SQ, Ftouni S, Lam EYN, Anderson MA, Pott C, Gilan O, Bell CC, Knezevic K, Blombery P, Rayeroux K, Zordan A, Li J, Huang DCS, Wall M, Seymour JF, Gray DHD, Roberts AW, Dawson MA, Dawson SJ.

Nat Med. 2019 Jan;25(1):119-129. doi: 10.1038/s41591-018-0243-z. Epub 2018 Nov 19.

PMID:
30455436
6.

Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma.

Davids MS, von Keudell G, Portell CA, Cohen JB, Fisher DC, Foss F, Roberts AW, Seymour JF, Humerickhouse RA, Tam CS.

J Clin Oncol. 2018 Oct 25:JCO1800359. doi: 10.1200/JCO.18.00359. [Epub ahead of print] No abstract available.

PMID:
30359156
7.

AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies.

Caenepeel S, Brown SP, Belmontes B, Moody G, Keegan KS, Chui D, Whittington DA, Huang X, Poppe L, Cheng AC, Cardozo M, Houze J, Li Y, Lucas B, Paras NA, Wang X, Taygerly JP, Vimolratana M, Zancanella M, Zhu L, Cajulis E, Osgood T, Sun J, Damon L, Egan RK, Greninger P, McClanaghan JD, Gong J, Moujalled D, Pomilio G, Beltran P, Benes CH, Roberts AW, Huang DC, Wei A, Canon J, Coxon A, Hughes PE.

Cancer Discov. 2018 Dec;8(12):1582-1597. doi: 10.1158/2159-8290.CD-18-0387. Epub 2018 Sep 25.

PMID:
30254093
8.

Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia.

Moujalled DM, Pomilio G, Ghiurau C, Ivey A, Salmon J, Rijal S, Macraild S, Zhang L, Teh TC, Tiong IS, Lan P, Chanrion M, Claperon A, Rocchetti F, Zichi A, Kraus-Berthier L, Wang Y, Halilovic E, Morris E, Colland F, Segal D, Huang D, Roberts AW, Maragno AL, Lessene G, Geneste O, Wei AH.

Leukemia. 2018 Sep 10. doi: 10.1038/s41375-018-0261-3. [Epub ahead of print]

PMID:
30214012
9.

A Map of Toll-like Receptor Expression in the Intestinal Epithelium Reveals Distinct Spatial, Cell Type-Specific, and Temporal Patterns.

Price AE, Shamardani K, Lugo KA, Deguine J, Roberts AW, Lee BL, Barton GM.

Immunity. 2018 Sep 18;49(3):560-575.e6. doi: 10.1016/j.immuni.2018.07.016. Epub 2018 Aug 28.

PMID:
30170812
10.

Glycaemic management during the inpatient enteral feeding of people with stroke and diabetes.

Roberts AW, Penfold S; Joint British Diabetes Societies (JBDS) for Inpatient Care.

Diabet Med. 2018 Aug;35(8):1027-1036. doi: 10.1111/dme.13678.

PMID:
30152589
11.

MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML.

Sanders MA, Chew E, Flensburg C, Zeilemaker A, Miller SE, Al Hinai AS, Bajel A, Luiken B, Rijken M, Mclennan T, Hoogenboezem RM, Kavelaars FG, Fröhling S, Blewitt ME, Bindels EM, Alexander WS, Löwenberg B, Roberts AW, Valk PJM, Majewski IJ.

Blood. 2018 Oct 4;132(14):1526-1534. doi: 10.1182/blood-2018-05-852566. Epub 2018 Jul 26.

12.

Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.

Davids MS, Hallek M, Wierda W, Roberts AW, Stilgenbauer S, Jones JA, Gerecitano JF, Kim SY, Potluri J, Busman T, Best A, Verdugo ME, Cerri E, Desai M, Hillmen P, Seymour JF.

Clin Cancer Res. 2018 Sep 15;24(18):4371-4379. doi: 10.1158/1078-0432.CCR-17-3761. Epub 2018 Jun 12.

PMID:
29895707
13.

Buprenorphine Use and Spending for Opioid Use Disorder Treatment: Trends From 2003 to 2015.

Roberts AW, Saloner B, Dusetzina SB.

Psychiatr Serv. 2018 Jul 1;69(7):832-835. doi: 10.1176/appi.ps.201700315. Epub 2018 May 8.

14.

Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.

Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, Jurczak W, Mulligan SP, Schuh A, Assouline S, Wendtner CM, Roberts AW, Davids MS, Bloehdorn J, Munir T, Böttcher S, Zhou L, Salem AH, Desai M, Chyla B, Arzt J, Kim SY, Verdugo M, Gordon G, Hallek M, Wierda WG.

J Clin Oncol. 2018 Jul 1;36(19):1973-1980. doi: 10.1200/JCO.2017.76.6840. Epub 2018 May 1.

PMID:
29715056
15.

Functional Characterization of a Glycosyltransferase from the Moss Physcomitrella patens Involved in the Biosynthesis of a Novel Cell Wall Arabinoglucan.

Roberts AW, Lahnstein J, Hsieh YSY, Xing X, Yap K, Chaves AM, Scavuzzo-Duggan TR, Dimitroff G, Lonsdale A, Roberts E, Bulone V, Fincher GB, Doblin MS, Bacic A, Burton RA.

Plant Cell. 2018 Jun;30(6):1293-1308. doi: 10.1105/tpc.18.00082. Epub 2018 Apr 19.

PMID:
29674386
16.

Reviewing state-mandated training requirements for naloxone-dispensing pharmacists.

Roberts AW, Carpenter DM, Smith A, Look KA.

Res Social Adm Pharm. 2018 Apr 5. pii: S1551-7411(17)30915-4. doi: 10.1016/j.sapharm.2018.04.002. [Epub ahead of print]

PMID:
29650444
17.

Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.

Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, Burbury K, Turner G, Di Iulio J, Bressel M, Westerman D, Lade S, Dreyling M, Dawson SJ, Dawson MA, Seymour JF, Roberts AW.

N Engl J Med. 2018 Mar 29;378(13):1211-1223. doi: 10.1056/NEJMoa1715519.

18.

Cellulose synthase 'class specific regions' are intrinsically disordered and functionally undifferentiated.

Scavuzzo-Duggan TR, Chaves AM, Singh A, Sethaphong L, Slabaugh E, Yingling YG, Haigler CH, Roberts AW.

J Integr Plant Biol. 2018 Jun;60(6):481-497. doi: 10.1111/jipb.12637. Epub 2018 Mar 30.

PMID:
29380536
19.

Direct observation of the effects of cellulose synthesis inhibitors using live cell imaging of Cellulose Synthase (CESA) in Physcomitrella patens.

Tran ML, McCarthy TW, Sun H, Wu SZ, Norris JH, Bezanilla M, Vidali L, Anderson CT, Roberts AW.

Sci Rep. 2018 Jan 15;8(1):735. doi: 10.1038/s41598-017-18994-4.

20.

Venetoclax: a primer.

Roberts AW.

Blood Adv. 2017 Feb 28;1(7):467. doi: 10.1182/bloodadvances.2017000547. eCollection 2017 Feb 28. No abstract available.

21.

Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis.

Pardanani A, Gotlib J, Roberts AW, Wadleigh M, Sirhan S, Kawashima J, Maltzman JA, Shao L, Gupta V, Tefferi A.

Leukemia. 2018 Apr;32(4):1035-1038. doi: 10.1038/leu.2017.330. Epub 2017 Nov 16. No abstract available.

PMID:
29263442
22.

Tissue-Resident Macrophages Are Locally Programmed for Silent Clearance of Apoptotic Cells.

Roberts AW, Lee BL, Deguine J, John S, Shlomchik MJ, Barton GM.

Immunity. 2017 Nov 21;47(5):913-927.e6. doi: 10.1016/j.immuni.2017.10.006. Epub 2017 Nov 14.

23.

Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM.

Moreau P, Chanan-Khan A, Roberts AW, Agarwal AB, Facon T, Kumar S, Touzeau C, Punnoose EA, Cordero J, Munasinghe W, Jia J, Salem AH, Freise KJ, Leverson JD, Enschede SH, Ross JA, Maciag PC, Verdugo M, Harrison SJ.

Blood. 2017 Nov 30;130(22):2392-2400. doi: 10.1182/blood-2017-06-788323. Epub 2017 Aug 28.

24.

Bisphosphonate guidelines for treatment and prevention of myeloma bone disease.

Lee OL, Horvath N, Lee C, Joshua D, Ho J, Szer J, Quach H, Spencer A, Harrison S, Mollee P, Roberts AW, Talaulikar D, Brown R, Augustson B, Ling S, Jaksic W, Gibson J, Kalff A, Johnston A, Kalro A, Ward C, Prince HM, Zannettino A.

Intern Med J. 2017 Aug;47(8):938-951. doi: 10.1111/imj.13502.

PMID:
28782211
25.

Functional Specialization of Cellulose Synthase Isoforms in a Moss Shows Parallels with Seed Plants.

Norris JH, Li X, Huang S, Van de Meene AML, Tran ML, Killeavy E, Chaves AM, Mallon B, Mercure D, Tan HT, Burton RA, Doblin MS, Kim SH, Roberts AW.

Plant Physiol. 2017 Sep;175(1):210-222. doi: 10.1104/pp.17.00885. Epub 2017 Aug 2.

26.

Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.

Teh TC, Nguyen NY, Moujalled DM, Segal D, Pomilio G, Rijal S, Jabbour A, Cummins K, Lackovic K, Blombery P, Thompson E, Ekert PG, Lessene G, Glaser SP, Huang DCS, Roberts AW, Guthridge MA, Wei AH.

Leukemia. 2018 Feb;32(2):303-312. doi: 10.1038/leu.2017.243. Epub 2017 Jul 28.

PMID:
28751770
27.

Targeting BCL-2-like Proteins to Kill Cancer Cells.

Cory S, Roberts AW, Colman PM, Adams JM.

Trends Cancer. 2016 Aug;2(8):443-460. doi: 10.1016/j.trecan.2016.07.001. Epub 2016 Jul 30. Review.

PMID:
28741496
28.

Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax.

Anderson MA, Tam C, Lew TE, Juneja S, Juneja M, Westerman D, Wall M, Lade S, Gorelik A, Huang DCS, Seymour JF, Roberts AW.

Blood. 2017 Jun 22;129(25):3362-3370. doi: 10.1182/blood-2017-01-763003. Epub 2017 May 4.

29.

Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia.

Bradstock KF, Link E, Di Iulio J, Szer J, Marlton P, Wei AH, Enno A, Schwarer A, Lewis ID, D'Rozario J, Coyle L, Cull G, Campbell P, Leahy MF, Hahn U, Cannell P, Tiley C, Lowenthal RM, Moore J, Cartwright K, Cunningham I, Taper J, Grigg A, Roberts AW, Benson W, Hertzberg M, Deveridge S, Rowlings P, Mills AK, Gill D, Bardy P, Campbell L, Seymour JF; Australasian Leukaemia & Lymphoma Group.

J Clin Oncol. 2017 May 20;35(15):1678-1685. doi: 10.1200/JCO.2016.70.6374. Epub 2017 Apr 3.

PMID:
28368672
30.

Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia.

Roberts AW, Stilgenbauer S, Seymour JF, Huang DCS.

Clin Cancer Res. 2017 Aug 15;23(16):4527-4533. doi: 10.1158/1078-0432.CCR-16-0955. Epub 2017 Jan 18. Review.

31.

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.

Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, Puvvada S, Kipps TJ, Anderson MA, Salem AH, Dunbar M, Zhu M, Peale F, Ross JA, Gressick L, Desai M, Kim SY, Verdugo M, Humerickhouse RA, Gordon GB, Gerecitano JF.

J Clin Oncol. 2017 Mar 10;35(8):826-833. doi: 10.1200/JCO.2016.70.4320. Epub 2017 Jan 17.

32.

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.

Seymour JF, Ma S, Brander DM, Choi MY, Barrientos J, Davids MS, Anderson MA, Beaven AW, Rosen ST, Tam CS, Prine B, Agarwal SK, Munasinghe W, Zhu M, Lash LL, Desai M, Cerri E, Verdugo M, Kim SY, Humerickhouse RA, Gordon GB, Kipps TJ, Roberts AW.

Lancet Oncol. 2017 Feb;18(2):230-240. doi: 10.1016/S1470-2045(17)30012-8. Epub 2017 Jan 13.

33.

Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.

Talaulikar D, Tam CS, Joshua D, Ho JP, Szer J, Quach H, Spencer A, Harrison S, Mollee P, Roberts AW, Horvath N, Lee C, Zannettino A, Brown R, Augustson B, Jaksic W, Gibson J, Kalff A, Johnston A, Trotman J, Kalro A, Grigoriadis G, Ward C, Prince HM.

Intern Med J. 2017 Jan;47(1):35-49. doi: 10.1111/imj.13311.

PMID:
28076910
34.

Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies.

Roberts AW, Huang D.

Clin Pharmacol Ther. 2017 Jan;101(1):89-98. doi: 10.1002/cpt.553. Epub 2016 Nov 26. Review.

35.

Targeting apoptotic pathways to treat lymphoid malignancies.

Roberts AW.

Rinsho Ketsueki. 2016;57(10):2054-2058.

PMID:
27795514
36.

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.

Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le Toumelin-Braizat G, Chanrion M, Kelly GL, Gong JN, Moujalled DM, Bruno A, Csekei M, Paczal A, Szabo ZB, Sipos S, Radics G, Proszenyak A, Balint B, Ondi L, Blasko G, Robertson A, Surgenor A, Dokurno P, Chen I, Matassova N, Smith J, Pedder C, Graham C, Studeny A, Lysiak-Auvity G, Girard AM, Gravé F, Segal D, Riffkin CD, Pomilio G, Galbraith LC, Aubrey BJ, Brennan MS, Herold MJ, Chang C, Guasconi G, Cauquil N, Melchiore F, Guigal-Stephan N, Lockhart B, Colland F, Hickman JA, Roberts AW, Huang DC, Wei AH, Strasser A, Lessene G, Geneste O.

Nature. 2016 Oct 27;538(7626):477-482. doi: 10.1038/nature19830. Epub 2016 Oct 19.

PMID:
27760111
37.

Lock-In Programs and the Opioid Epidemic: A Call for Evidence.

Roberts AW, Gellad WF, Skinner AC.

Am J Public Health. 2016 Nov;106(11):1918-1919. No abstract available.

38.

Controlled Substance Lock-In Programs: Examining An Unintended Consequence Of A Prescription Drug Abuse Policy.

Roberts AW, Farley JF, Holmes GM, Oramasionwu CU, Ringwalt C, Sleath B, Skinner AC.

Health Aff (Millwood). 2016 Oct 1;35(10):1884-1892.

PMID:
27702963
39.

Rapid Inflammation in Mice Lacking Both SOCS1 and SOCS3 in Hematopoietic Cells.

Ushiki T, Huntington ND, Glaser SP, Kiu H, Georgiou A, Zhang JG, Metcalf D, Nicola NA, Roberts AW, Alexander WS.

PLoS One. 2016 Sep 1;11(9):e0162111. doi: 10.1371/journal.pone.0162111. eCollection 2016.

40.

Reducing Opioid Misuse: Evaluation of a Medicaid Controlled Substance Lock-In Program.

Skinner AC, Ringwalt C, Naumann RB, Roberts AW, Moss LA, Sachdeva N, Weaver MA, Farley J.

J Pain. 2016 Nov;17(11):1150-1155. doi: 10.1016/j.jpain.2016.07.003. Epub 2016 Aug 4.

PMID:
27497767
41.

Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1.

Gong JN, Khong T, Segal D, Yao Y, Riffkin CD, Garnier JM, Khaw SL, Lessene G, Spencer A, Herold MJ, Roberts AW, Huang DCS.

Blood. 2016 Oct 6;128(14):1834-1844. doi: 10.1182/blood-2016-03-704908. Epub 2016 Jul 27.

42.

Comparative Structural and Computational Analysis Supports Eighteen Cellulose Synthases in the Plant Cellulose Synthesis Complex.

Nixon BT, Mansouri K, Singh A, Du J, Davis JK, Lee JG, Slabaugh E, Vandavasi VG, O'Neill H, Roberts EM, Roberts AW, Yingling YG, Haigler CH.

Sci Rep. 2016 Jun 27;6:28696. doi: 10.1038/srep28696.

43.

Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.

Khaw SL, Suryani S, Evans K, Richmond J, Robbins A, Kurmasheva RT, Billups CA, Erickson SW, Guo Y, Houghton PJ, Smith MA, Carol H, Roberts AW, Huang DC, Lock RB.

Blood. 2016 Sep 8;128(10):1382-95. doi: 10.1182/blood-2016-03-707414. Epub 2016 Jun 24.

44.

Nephrotic syndrome as a complication of chronic graft-versus-host disease after allogeneic haemopoietic stem cell transplantation.

Wong E, Lasica M, He SZ, Bajel A, Roberts AW, Mason KD, Ritchie DS, Szer J.

Intern Med J. 2016 Jun;46(6):737-41. doi: 10.1111/imj.13098.

PMID:
27257151
45.

New Agents to Treat Chronic Lymphocytic Leukemia.

Roberts AW, Davids MS, Seymour JF.

N Engl J Med. 2016 Jun 2;374(22):2186-7. doi: 10.1056/NEJMc1602674. No abstract available.

PMID:
27248631
46.

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.

Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, Puvvada SD, Wendtner CM, Roberts AW, Jurczak W, Mulligan SP, Böttcher S, Mobasher M, Zhu M, Desai M, Chyla B, Verdugo M, Enschede SH, Cerri E, Humerickhouse R, Gordon G, Hallek M, Wierda WG.

Lancet Oncol. 2016 Jun;17(6):768-778. doi: 10.1016/S1470-2045(16)30019-5. Epub 2016 May 10.

PMID:
27178240
47.

The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.

Anderson MA, Deng J, Seymour JF, Tam C, Kim SY, Fein J, Yu L, Brown JR, Westerman D, Si EG, Majewski IJ, Segal D, Heitner Enschede SL, Huang DC, Davids MS, Letai A, Roberts AW.

Blood. 2016 Jun 23;127(25):3215-24. doi: 10.1182/blood-2016-01-688796. Epub 2016 Apr 11.

48.

BET inhibition represses miR17-92 to drive BIM-initiated apoptosis of normal and transformed hematopoietic cells.

Xu Z, Sharp PP, Yao Y, Segal D, Ang CH, Khaw SL, Aubrey BJ, Gong J, Kelly GL, Herold MJ, Strasser A, Roberts AW, Alexander WS, Burns CJ, Huang DC, Glaser SP.

Leukemia. 2016 Jul;30(7):1531-41. doi: 10.1038/leu.2016.52. Epub 2016 Mar 8.

PMID:
27055867
49.

Progress in BCL2 inhibition for patients with chronic lymphocytic leukemia.

Tam CS, Seymour JF, Roberts AW.

Semin Oncol. 2016 Apr;43(2):274-9. doi: 10.1053/j.seminoncol.2016.02.014. Epub 2016 Feb 6. Review.

PMID:
27040706
50.

Immuno and Affinity Cytochemical Analysis of Cell Wall Composition in the Moss Physcomitrella patens.

Berry EA, Tran ML, Dimos CS, Budziszek MJ Jr, Scavuzzo-Duggan TR, Roberts AW.

Front Plant Sci. 2016 Mar 8;7:248. doi: 10.3389/fpls.2016.00248. eCollection 2016.

Supplemental Content

Loading ...
Support Center